Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Scopolamine
Drug ID BADD_D01994
Description Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient than extracting scopolamine from plants.[A228763] As an acetylcholine analogue, scopolamine can antagonize muscarinic acetylcholine receptors (mAChRs) in the central nervous system and throughout the body, inducing several therapeutic and adverse effects related to alteration of parasympathetic nervous system and cholinergic signalling.[A228758, L31578] Due to its dose-dependent adverse effects, scopolamine was the first drug to be offered commercially as a transdermal delivery system, Scopoderm TTS®, in 1981.[A228423, A228758] As a result of its anticholinergic effects, scopolamine is being investigated for diverse therapeutic applications; currently, it is approved for the prevention of nausea and vomiting associated with motion sickness and surgical procedures.[A228773, L31578] Scopolamine was first approved by the FDA on December 31, 1979, and is currently available as both oral tablets and a transdermal delivery system.[L31578]
Indications and Usage For the treatment of excessive salivation, colicky abdominal pain, bradycardia, sialorrhoea, diverticulitis, irritable bowel syndrome and motion sickness.
Marketing Status Prescription
ATC Code A04AD01; N05CM05; S01FA02
DrugBank ID DB00747
KEGG ID D00138
MeSH ID D012601
PubChem ID 5184
TTD Drug ID D0B7YT
NDC Product Code 0378-6470; 0067-4346; 50742-505; 51886-0501; 48954-540; 50090-5349; 68404-1004; 55742-126
Synonyms Scopolamine | Hyoscine | Transderm Scop | Scopoderm TTS | Transderm-V | Transderm V | Travacalm HO | Vorigeno | Boro-Scopol | Boro Scopol | Isopto Hyoscine | Kwells | Scoburen | Scopace | Scopolamine Cooper | Scopolamine Hydrobromide
Chemical Information
Molecular Formula C17H21NO4
CAS Registry Number 51-34-3
SMILES CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Memory impairmentTumor necrosis factorP16599Not Available25711042
Memory impairmentAcetylcholinesteraseP37136Not Available25711042
Memory impairmentDNA (cytosine-5)-methyltransferase 1P26358T8830425982413
Memory impairmentHistone deacetylase 2Q92769T5119125982413
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dysuria20.02.02.002--
Ear disorder04.03.01.001--Not Available
Eczema23.03.04.006--
Erythema23.03.06.0010.001861%Not Available
Eye disorder06.08.03.001--Not Available
Eye pain06.08.03.0020.001861%
Fatigue08.01.01.002--
Feeling abnormal08.01.09.0140.001861%Not Available
Flushing23.06.05.003; 08.01.03.025; 24.03.01.002--
Hallucination19.10.02.0020.004651%
Hallucination, visual19.10.02.004--Not Available
Headache17.14.01.0010.001861%
Heart rate abnormal13.14.04.006--Not Available
Heat exhaustion12.05.01.003--Not Available
Heat stroke24.06.02.009; 12.05.01.001--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypokalaemia14.05.03.0020.001861%
Hypotension24.06.03.002--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.001861%
Malaise08.01.01.0030.003721%
Memory impairment19.20.01.003; 17.03.02.003--
Muscular weakness17.05.03.005; 15.05.06.001--
Mydriasis06.05.03.004; 17.02.11.0030.008372%Not Available
Nausea07.01.07.0010.011163%
Nervous system disorder17.02.10.001--Not Available
Ocular hyperaemia06.04.05.0040.001861%Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Pain08.01.08.0040.001861%
Paranoia19.05.01.005--Not Available
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages